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Development of strategies for induction of HIV-1
broadly neutralizing antibodies (bnAbs) by vaccines
is a priority. Determining the steps of bnAb induction
in HIV-1-infected individuals who make bnAbs is a
key strategy for immunogen design. Here, we study
the B cell response in a bnAb-producing individual
and report cooperation between two B cell lineages
to drive bnAb development. We isolated a virus-
neutralizing antibody lineage that targeted an enve-
lope region (loop D) and selected virus escape
mutants that resulted in both enhanced bnAb lineage
envelope binding and escape mutant neutraliza-
tion—traits associated with increased B cell antigen
drive. Thus, in this individual, two B cell lineages
cooperated to induce the development of bnAbs.
Design of vaccine immunogens that simultaneously
drive both helper and broadly neutralizing B cell
lineages may be important for vaccine-induced reca-
pitulation of events that transpire during the matura-
tion of neutralizing antibodies in HIV-1-infected
individuals.
INTRODUCTION
The development of a successful HIV-1 vaccine has been sty-
mied by the inability to induce broadly neutralizing antibodies(bnAbs) to regions of the HIV-1 envelope glycoprotein (Env)
(Burton et al., 2012; Mascola and Haynes, 2013) that in-
clude the CD4-binding site (CD4bs); the membrane proximal-
external region; and glycans and amino acid residues in the
regions of the first (V1), second (V2), and third (V3) loops (Burton
et al., 2012; Kwong and Mascola, 2012; Sattentau and
McMichael, 2010; Stamatatos, 2012; Walker et al., 2011; Walker
et al., 2009; Zhou et al., 2010). To date, all bnAbs isolated have
one or more unusual characteristics: high levels of somatic
hypermutations, long heavy chain third complementarity deter-
mining regions (HCDR3), or poly- or auto-reactivity to non-
HIV-1 antigens (Haynes et al., 2005; Haynes et al., 2012; Kwong
and Mascola, 2012; Mouquet and Nussenzweig, 2012; Scheid
et al., 2009)—all antibody traits influenced by various host toler-
ance mechanisms (Haynes et al., 2012; Mascola and Haynes,
2013; Mouquet and Nussenzweig, 2012). As a consequence of
these antibody traits, bnAbs appear to be disfavored and difficult
to induce with traditional immunization regimens (Haynes et al.,
2012; Mascola and Haynes, 2013; Mascola and Montefiori,
2010; Montefiori et al., 2012). We and others have suggested
strategies whereby immunogens are selected to react with
bnAb lineage members at multiple stages in their development
in an effort to drive otherwise unfavored antibody pathways
(Haynes et al., 2012; Liao et al., 2013a; Mascola and Haynes,
2013).
One approach to dissect the mechanisms underlying bnAb
development is to identify the drivers that are responsible for
the sequential stimulation of HIV-1 reactive B cell lineages in
chronically infected individuals over time (Bonsignori et al.,
2011; Corti et al., 2010; Gray et al., 2011; Hraber et al., 2014;Cell 158, 481–491, July 31, 2014 ª2014 Elsevier Inc. 481
Figure 1. Neutralization Activity of CH103 Clonal Lineage Antibodies
against Autologous CH505 Viruses
Heat map analysis of neutralization data generated from 124 pseudoviruses
(row) and 13CH103 lineagemAbs (column). The neutralization potency (IC50) is
shown in different shades of colors as indicated in the histogram, from white
(>50 mg/ml) to dark red (0.079 mg/ml). The Env pseudoviruses were generated
for the CH505 T/F virus and variants from weeks 4–100 and were all assayed
against the unmutated common ancestor (UCA), intermediate antibodies
(IA8-1), and mature bnAbs (CH103-106) in the TZM-bl cell-based neutraliza-
482 Cell 158, 481–491, July 31, 2014 ª2014 Elsevier Inc.Klein et al., 2012; Lynch et al., 2012; Moore et al., 2009; Moore
et al., 2011; Tomaras et al., 2011; Walker et al., 2011). We have
recently identified an African individual (CH505) in whom HIV-1
infection was established by a single subtype C transmitted/
founder (T/F) virus and mapped the coevolution of CD4bs bnAbs
(the CH103 bnAb B cell lineage) and CH505 T/F virus over time
(Liao et al., 2013a). The T/F Env continuously diversified over
time under the selection pressure of bnAbs and, concurrently,
the inferred unmutated common ancestor (UCA) of the CH103
B cell lineage accumulated somatic mutations leading to gradual
acquisition of bnAb activity (Liao et al., 2013a). While the mini-
mally mutated early members of this lineage neutralized only
the T/F virus, the later, more mature members of the CH103
clonal lineage potently neutralized both the CH505 T/F and
55% of multiclade heterologous HIV-1 strains (Liao et al.,
2013a). These data engendered interest in determining the autol-
ogous virus Env variants that stimulated the development of this
broadly neutralizing CH103 antibody lineage. Cocrystal structure
of the CH103 antibody and the HIV-1 Env revealed antibody con-
tacts in the V5, CD4-binding loop, and loop D regions in Env, and
analysis of the env gene sequences obtained by single-genome
amplification demonstrated additional early mutations in the V1
and V4 loop regions (Liao et al., 2013a).
In this study, we have probed the mechanisms of selection of
early CH505 Env mutations and found that amino acid changes
in the V1, V4, V5, and CD4-binding loops resulted in escape from
neutralization by the CH103 lineage (V1, V5, CD4-binding loop)
or from cytotoxic T cell pressure (V4). Surprisingly, however,
the mutations in the Env loop D increased neutralization sensi-
tivity to the CH103 bnAb lineage. We demonstrated a mecha-
nism of bnAb induction wherein a second antibody lineage
targeted a bnAb contact site, thus selecting Env variants with
enhanced binding and neutralization sensitivity for bnAb lineage
antibodies. These results demonstrated that cooperation be-
tween two B cell lineages early in HIV-1 infection can facilitate
the induction of broadly neutralizing CD4bs antibodies.
RESULTS
Early CH505 Env Mutations in V1, V4, V5, and the CD4bs
Were Associated with Escape from CH103 bnAbs or
T Cell Responses
To study the interplay between HIV-1 Env variants and bnAb
development in the CH505 individual, we determined neutraliza-
tion susceptibility of 124 Env pseudoviruses (18 per time point)
from seven time points after HIV-1 transmission (weeks 4, 14, 20,
30, 53, 78, and 100) to members of the CH103 bnAb lineage (Fig-
ures 1 and S1 available online). The CH103 UCA and intermedi-
ate antibody (IA) 8 through IA4 only neutralized the CH505 T/F
virus. Over time (weeks 4–100), CH505 viruses gradually became
more resistant to subsets of the CH103 bnAb lineage antibodies.
Byweek 53, all virus variants were resistant to the earlymemberstion assay. The resistant viruses (blue brackets) were defined as those with the
average IC50 values 1.8-fold higher than that of the T/F pseudoviruses for later
IAs (IA3-IA1) and all mature Abs. The week 30 viruses that escaped from the
early IAs (IA8-IA4) are also indicated by blue bracket. See also Table S1 and
Figures S1 and S4.
A B Figure 2. Association of Insertions in V1 and
V5 with Neutralization Escape from CH103
Lineage mAbs
(A and B) The V1 (A) and V5 (B) amino acid se-
quences at week 30 were compared to the CH505
T/F sequence. The neutralization sensitive viruses
to early IAs (IA8-4) and late IAs (IA3-1)/mature
CH103 lineage mAbs (CH103-106) are indicated in
red and blue, respectively. The PNLG sites are
indicated in yellow. The identical amino acids are
shown as dashes and deletions are shown as dots.
See also Figures S1 and S2.of the CH103 antibody lineage (UCA and IA8-4). For lineage
members that exhibited increased heterologous neutralization
(IA3-IA1 and mature CH103, CH104, CH105, and CH106
CD4bs bnAbs), escape was less complete, with a spectrum of
sensitive and resistant autologous virus variants isolated from
each time point (Figure 1 and Table S1). Thus, pseudoviruses
were categorized into sensitive and resistant groups and
analyzed for location of accumulated mutations in the env
gene (Figure 1).
Env sequence analysis showed that all but 1 of the 20 viruses
resistant to early IAs (IA8-IA4) at week 30 contained insertions
(3–12 amino acids) in V1 (Figure 2A). Importantly, the V1 inser-
tions also added 1–4 potential N-linked glycosylation (PNLG)
sites (Figures 2A and S2). Although V1 was not seen in the
Env-CH103 cocrystal structure (Liao et al., 2013a), a recent
cryo-EM structure of the fully glycosylated Env trimer showed
that V1/V2 could significantly affect the binding and neutraliza-
tion of CD4bs bnAbs (Lyumkis et al., 2013). Docking the
CH103 bnAb and CH505 Env sequences on the cryo-EM struc-
ture showed that an enlarged V1 loop with potential extra
glycan(s) might push V2 into positions incompatible with early
IA binding (Figures S2A and S2B). All but one of the 16 viruses
resistant to later IAs (IA3-IA1) and mature CH103 mAbs had a
two or seven amino acid insertions in V5, which is a major Env
contact site for the CH103 bnAb heavy chain (Liao et al.,
2013a). All resistant viruses from weeks 53, 78, and 100 had in-
sertions in V5 (Figures 1 and S1). The two amino acid (Asp and
Thr) insertions could push loop V5 and the glycan at position
461 into a possible clashing position with the light chain of
CH103 antibodies (Figure S2C). Introduction of the Asp and
Thr into V5 in the T/F Env confirmed that this two amino acid
insertion indeed conferred resistance to CH103 lineage mAbs
(Figure S2D). We also found one mutation (S365P) in the CD4-
binding loop that resulted in a pseudovirus (w14.12) that
completely escaped from all members of the CH103 lineage
except for weak neutralization susceptibility to mAb CH103 (Fig-Cell 158, 481–ures 1 and S1). These results indicated
that early insertions in the V1 and V5
loops as well as site mutations in the
CD4-binding loop resulted from CH103
bnAb mediated selection pressure.
Mutations in V4 were found early on at
week 7 and persisted throughout later
time points, suggesting that they werestrongly selected (Figure S1). Viruses with mutations in a nine
amino acid region in V4 were predominant (78%) as early as
week 7 and completely replaced the T/F virus population from
week 14 onward (Figures S1 and S3A). The N279K mutation in
loop D was detected at as early as week 4 (10%), peaked at
week 7 (57%), and disappeared from week 14 onward (Figures
3A and S1). In addition, the V281A and V281G mutations were
detected at week 7 and week 9, respectively, and both become
predominant in later time points together with other mutations in
a nine amino acid region in loop D (Figure 3A). Since the muta-
tions in both regions occurred early and their patterns were
typical for T cell escape mutations, we performed ELISpot anal-
ysis using autologous overlapping peptides to determine if those
mutations were driven by CD8+ T cell responses.
A CD8+ T cell response was detected for a putative T cell
epitope (NSTRTITIHC) in V4 (Figure S3B and Table S2). The
same peptides containing a T415K mutation, which were de-
tected at week 14, could not be recognized by CD8+ T cells.
Four mutants containing individual V4 mutations, including
the T415K, had similar neutralization susceptibility to CH103
lineage mAbs as the T/F virus (Figure S3C). These results
demonstrated that the predominant mutations in V4 were
driven by CD8+ T cell responses. In contrast, no T cell re-
sponses were found targeting the loop D or V1, V3, and V5
regions (Table S2).
Selection of the Loop DMutations in CH505 Envelope by
Neutralizing Non-CH103 Abs
Since the Env loop D region is a binding site for CH103 lineage
bnAbs (Liao et al., 2013a), we next asked if loop D mutations
might be due to the selection by CH103 lineage CD4bs anti-
bodies. To test this hypothesis, we introduced loop D mutations
at positions 275, 279, 280, and 281, individually or in combina-
tion as they occurred in vivo, into the T/F env gene to determine
their effect on Env pseudovirus sensitivity to neutralization by the
autologous CH103 lineage mAbs. Unexpectedly, all loop D491, July 31, 2014 ª2014 Elsevier Inc. 483
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Figure 3. Mutations in Loop D Rendered the Env Mutants More Sensitive to CH103 Lineage bnAb Neutralization with Enhanced Env Binding
(A) Alignment of nine amino acids in loop D of Env. The amino acid sequences fromweek 4 to week 160 were compared to the CH505 T/F sequence. The number
and frequency of each variant in loopD are shown at the right of the alignment. The amino acids that interact with theCH103 light chain are indicated in yellow. The
loop D mutations that occurred early or predominated are indicated in red, and Env mutants containing those mutations are indicated by red arrows.
(B) Neutralization susceptibility of the loop D mutants to the CH103 lineage mAbs. Heatmap analysis was performed for the neutralization data of all CH103
lineage mAbs (column) against the CH505 T/F virus and the loop D variants (row). The neutralization potency (IC50) is shown in different colors as indicated, from
white (>50 mg/ml) to dark red (0.12 mg/ml).
(C) Neutralization activity of the nAb CH235 were compared to that of the bnAb CH103 against the CH505 T/F virus and loop D mutants.
(D) The fold difference in binding to loop D mutant Envs versus the CH505 T/F Env by both CH103 and CH235 lineage Abs. Seven loop D mutant Envs (M6V281A,
M10V281G, M11N279D/V281G, M7E275K/N279D/V281S, M8N280S/V281A, M9E275K/N279D/V281G, and M21N280T/V281A) and the CH505 T/F Env were serially diluted and the log
area under the curve (AUC) values for all members of the CH103 and CH235 lineage mAbs were determined by ELISA. The fold difference in log AUC between
each loop D mutant Env versus the CH505 T/F Env is shown.
See also Figures S3, S4, and S6; Tables S2, S3, and S6.
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Figure 4. Neutralization Activity of the CH235 Clonal Lineage Anti-
bodies against Autologous CH505 Viruses
Heatmap analysis of neutralization data generated from 41 pseudoviruses
(row) and 10CH235 lineagemAbs (column). The neutralization potency (IC50) is
shown in different shades of colors as indicated in the histogram, from white
(>50 mg/ml) to dark red (0.1 mg/ml) (see also Table S4). The CH505 T/F and
select variant Env pseudoviruses from each time point (weeks 4–100) were
assayed against the unmutated common ancestor (UCA), intermediate anti-
bodies (IA4-1) and mature neutralizing antibodies (CH235, CH236, CH239,
CH240, and CH241) in the TZM-bl cell-based neutralization assay. The
partially and fully resistant viruses are indicated by the blue bracket. See also
Figure S5 and Table S4.mutations rendered the mutant Env pseudoviruses 4.5-fold
(range, 0.4–20) more sensitive than the T/F virus to neutralization
by CH103 lineage bnAbs (Figure 3B and Table S3). In addition,
when compared to the CH505 T/F virus, four loop D mutants
(M5N279K, M6V281A, M7E275K/N279D/V281S, and M10V281G) with
one or three mutations were less fit than the T/F virus (Fig-
ure S3D). These results demonstrated that the loop D mutationswere selected by an antibody lineage other than theCH103 bnAb
lineage.
To isolate the antibodies responsible for the loop Dmutations,
we established limiting dilution cell cultures from peripheral
bloodmemory B cells collected at week 41 in CH505 (Bonsignori
et al., 2011). We chose week 41 to study because neutralization
of heterologous tier 2 viruses was first detected at week 41,
21 weeks after the detection of the first autologous neutralization
activity. We identified one mAb, CH235 (VH1-46, Vk3-15), that
neutralized the CH505 T/F, but belonged to a clonal family
distinct from CH103 lineage (VH4-59, Vl3-1). mAb CH235
neutralized the CH505 T/F virus 7-fold more potently than
antibody CH103 (Figure 3C). However, CH235 poorly neutralized
loop D mutant M11N279D/V281G and could not neutralize five
other loop D mutants (M7E275K/N279D/V281S, M8N280S/V281A,
M9E275K/N279D/V281G, M20N280S/V281G, and M21N280T/V281A). In
contrast, CH103 neutralized the same five loop D mutants
10-fold better than the CH505 T/F virus (Figure 3C).
To identify antibody members of the CH235 lineage, we
analyzed limiting dilution memory B cell cultures from week 41
and identified four additional CH235 lineage members (CH236,
CH239, CH240, and CH241). The frequency of CH235 clonal
lineage memory B cells at week 41 posttransmission was
0.018%, which was similar to that (0.014%) of the CH103
bnAb lineage. The four CH103 lineage antibodies isolated at
week 41 were of similar mutation frequencies as inferred anti-
bodies of the neutralization arm of the CH103 lineage (Figure S4).
To confirm the relevance of the inferred IAs of the CH103 lineage,
we characterized these newly isolated four natural IAs (CH186,
CH187, CH188, and CH200) of the CH103 bnAb lineage from
week 41 and demonstrated that their neutralization specificity
was similar to that of the inferred IAs with only neutralization of
the autologous CH505 T/F virus and no neutralization of heterol-
ogous viruses (Figure S4).
We inferred the CH235 lineage UCA and IAs, and expressed all
CH235 lineage members as IgG1 recombinant antibodies (Liao
et al., 2013a) (Figure S5). We then determined the ability of the
CH235 lineage antibodies to neutralize the CH505 T/F and its
variants. Like CH103 lineage mAbs, the CH235 UCA did not
neutralize the CH505 T/F virus, with neutralization capacity
acquired at IA3 (Figure 4 and Table S4). The CH235 lineage
mAbs could partially neutralize week 30 viruses but could not
neutralize the majority of viruses from weeks 53–100 after
these viruses acquired loop D mutations. These results demon-
strated that CH235 lineage mAbs had an autologous neutraliza-
tion profile distinct from the CH103 bnAb lineage, in that they
potently neutralized early autologous viruses and then at week
53 selected viruses that completely escaped CH235 lineage
neutralization.
To determine whether the escape from CH235 lineage mAbs
was indeed due to loop D mutations, we determined the ability
of CH235 lineage mAbs to neutralize the CH505 loop Dmutants.
CH235 lineage antibodies neutralized the early loop D mutants
(M5N279K, M6V281A, M10V281G) that occurred before week 30
equally well or better than the T/F virus (Figure 5 and Table
S5). These mutants have only one mutation at position 279 or
281. However, the CH235 lineagemAbs only partially neutralized
loop D mutants M19V281D and M11N279D/V281G that were firstCell 158, 481–491, July 31, 2014 ª2014 Elsevier Inc. 485
Figure 5. Neutralization Activity of CH235 Clonal Lineage Antibodies
against CH505 Env Loop D Mutants
Heat map analysis of neutralization data generated from ten loop D mutants
(row) and ten CH235 lineage mAbs (column). The neutralization potency (IC50)
is shown in different shades of colors as indicated in the histogram, from white
(>50 mg/ml) to dark red (0.1 mg/ml). The CH505 T/F and loop D mutant Env
pseudoviruses were assayed against the unmutated common ancestor (UCA),
intermediate antibodies (IA4-1) and mature neutralizing antibodies (CH235,
CH236, CH239, CH240 and CH241) in the TZM-bl cell-based neutralization
assay. The partially and fully resistant viruses are indicated by the blue bracket.
See also Table S5.detected at week 30 and could not neutralize the five loop D
mutants representing CH505 variants at week 30 or later time
points (M8N280S/V281A, M9E275K/N279D/V281G, M7E275K/N279D/V281S,
M20N280S/V281G, and M21N280T/V281A). Thus, we have identified
a second clonal lineage (CH235) of neutralizing antibodies from
the CH505 individual that selected early loop D Env mutations.
Mutations in Loop D Enhance Interactions between Env
gp120 and CH103 bnAbs
Based on our previous cocrystal structure of Env and CH103
(Liao et al., 2013a), the T/F Env favored the interaction with
the CH103 UCA (Figure 6A). However, the loop D mutant
M7E275K/N279D/V281S that contained three mutations favorably
bound the mature CH103, which contained three CDR L2 muta-
tions (Q50E, D51N and S52Y) compared to the UCA (Figure 6B).
The E275K mutation in M7 rendered the Loop D positively
charged at one side and this change was complementarily
accommodated by a CDR L2 Q50E mutation in the mature
CH103. Similarly, the N279D mutation made the other side of
loop D more negatively charged to better complement the
CDR L2 Lys53. Computational reversion of critical mutations in
loop D and CDR L2, such as gp120 Asp279 and CH103 Tyr52,
back to those in the T/F Env and CH103 UCA, respectively,
resulted in less favorable binding energy (Figure 6C). This sug-
gested that the coevolution of the CH505 loop D and CH103 line-
age antibodies led to better binding between loop Dmutants and
mature CH103 antibodies, while the reversion mutations in either
Env or CH103 bnAb resulted in reduced binding. In the CH505
Env evolution, analysis of longitudinal sequences demonstrated486 Cell 158, 481–491, July 31, 2014 ª2014 Elsevier Inc.that single loop D Envmutations were selected early, followed by
multiple loop D mutations at later time points; most of these mu-
tations occurred at positions 279 and 281 (Figure 3A). The
sequential accumulation of mutations from simple to complex
forms in loop D might have gradually selected the mutations at
the binding site in CDR L2 with continuously increased binding
affinity. Thus, the improved binding between the loop D mutants
and CDR L2 of mature CH103 might have driven the further
maturation of CH103 lineage mAbs.
CH103 Lineage bnAbs Bound to the Loop DMutant Envs
More Efficiently Than the T/F Env
We next asked whether the CH505 Envs with the loop Dmutants
could bind to the CH103 lineagemembers better than the CH505
T/F Env, a trait thought to be necessary to drive antibody lineage
maturation (Dal Porto et al., 2002; Dal Porto et al., 1998;
Schwickert et al., 2011; Shih et al., 2002). Seven loop D mutant
Envs were expressed as gp140s, M6V281A and M10V281G with
individual mutations, M8N280S/V281A, M11N279D/V281G, and
M21N280T/V281A with two mutations, and M7E275K/N279D/V281S,
and M9E275K/N279D/V281G with three mutations (Figure 3B). We
then determined their binding by ELISA to all members in
the CH103 and CH235 lineages (Figure S6). The M6V281A,
M10V281G, and M11N279D/V281G loop D mutant Envs bound to
nearly all CH103 clonal lineage members better than the T/F
Env (Figure 3D), while M8N280S/V281A, M9E275K/N279D/V281G, and
M21N280T/V281A mutant Envs bound less well than the T/F Env
to early CH103 lineage members (UCA through IA4) (Figure 3D).
All seven loop D mutant Envs also bound to four natural IAs
(CH186, CH187, CH188, and CH200) of the CH103 bnAb lineage
better than the T/F Env (Figure S4D). Thus, it is likely that CH505
Env loop D mutant viruses drove the maturation of the CH103
lineage by targeting early lineage members through mutations
at amino acid positions 281 and 279, and late CH103 lineage
members by a combinations of mutations at amino acid posi-
tions 280, 281, 279, and/or 275 (Figures 3A and 3D).
In contrast, when compared to the T/F Env, mature CH235
mAbs and IA3-IA1 bound loop D mutant Envs at least 100-fold
lower than the T/F Env, except that they bound to M6V281A Env
better than the T/F Env (Figure 3D). While none of the loop Dmu-
tants or the CH505 T/F Env bound the CH235 UCA or IA4 by
ELISA, the T/F Env did weakly react with the CH235 UCA at
10 mM as determined by surface plasmon resonance (Table
S6). These results strongly supported the hypothesis that the
CH235 lineage mAbs selected the loop D mutant Envs that
had lower binding to theCH235 lineagemAbs, but higher binding
to, and enhanced neutralization by, the CH103 lineage mAbs
(Figure 7).
DISCUSSION
One fundamental question in HIV-1 vaccine design is how
immunogens can be optimized to drive the maturation of bnAbs
in vivo. By studying the HIV-1 quasispecies evolution in an indi-
vidual (CH505) with a single TF virus, and by mapping the
neutralization susceptibility of early quasispecies members to
the autologous CH103 lineage, we have shown that the matura-
tion of the CD4bs bnAb lineage was driven by cooperation of two
A B
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Figure 6. Evolutionary Mutations in the
Loop D and Antibody Facilitate Interactions
between gp120 and CH103 Lineage Anti-
bodies
(A) Model of CH505 T/F gp120 in complex with
UCA of CH103.
(B) Model of loop D mutant M7E275K/N279D/V281S
gp120 in complex with mature CH103. The gp120
is shown in semitransparent electrostatic potential
surface with red for negative charge and blue for
positive charge. The heavy and light chains of the
CH103 bnAb are shown in green and orange,
respectively. All critical mutations in loop D and
CDR L2 are highlighted in sticks and colored in
cyan for residues (279 and 281) in loop D, orange
for conserved CDR L2 Lys53, and blue for mutated
CDR L2 residues 50–52.
(C) Estimated binding affinity change when speci-
fied residues were reverted back to the T/F or
germline sequences for gp120 and CH103 light
chain, respectively. ‘‘--’’ indicates the calculated
binding energy was decreased by >1.0 kcal/mol,
‘‘-‘‘ indicates a decrease by 0.1-1.0 kcal/mol, and
‘‘+/’’ indicates calculated energies were about
the same. Reversion of residues, such as Loop D
Asp279 and CDR L2 Tyr52, resulted in weaker
binding, suggesting that the evolution of both
gp120 loop D and CDR L2 of CH103 facilitated the
interaction between HIV-1 gp120 and mature
CH103 antibodies.neutralizing antibody B cell lineages. This observation came from
the surprising finding that one of the contact sites of the CH103
bnAb light chain (the Env loop D) contained mutations that did
not lead to escape from the CH103 bnAb lineage, but, in
contrast, resulted in enhanced binding and neutralization of
loop D mutant viruses by the CH103 bnAb lineage. These data
demonstrated that the CH103 bnAb lineage members did not
select the loop D mutants in CH505 Env, but rather suggested
the existence of antibodies that could neutralize the CH505 T/F
virus, but not neutralize loop D mutant viruses. Thus, these ob-
servations led to the isolation of the CH235 lineage, and the
demonstration that this neutralizing lineage indeed selected
CH505 transmitted/founder virus loop D escape mutants.
The concept of bnAbs evolving from autologous neutralizing
antibody lineages has been recently put forth (Doria-Rose
et al., 2014; Liao et al., 2013a; Moore et al., 2012; Wibmer
et al., 2013). Moore and colleagues demonstrated that autolo-
gous polyclonal plasma neutralizing antibodies targeted at sub-
sequent sites of V1V2 bnAbs could be documented (Moore et al.,
2012; Wibmer et al., 2013). Our studies differ from these studies
in that we have used recombinant antibody techniques to isolate
entire clonal lineages to directly demonstrate their cooperation in
induction of CD4bs bnAbs. While it is clear that bnAbs develop
heterologous broad neutralizing capacity by first neutralizing
autologous virus Env mutant viruses (Doria-Rose et al., 2014;
Liao et al., 2013a), our study directly demonstrates a mechanism
of how this can happen at the B cell lineage level. These obser-
vations of two lineages cooperating to drive a bnAb lineage pro-
vide a view of how one lineage can be affected by another toaccommodate autologous Env variation. Thus, the cooperation
between the CH235 and CH103 lineages represents a novel
molecular mechanism of bnAb development, wherein one
neutralizing lineage (CH235) selected escape mutations in an
Env contact site (loop D) that led to increased binding and
neutralization of the other bnAb lineage (CH103), ultimately
driving the maturation and development of broadly cross-reac-
tive neutralizing antibodies (Figure 7). It has been unclear how
bnAbs can acquire heterologous breadth of neutralization in
response to evolving T/F variants. Our studies show that one
mechanism for achieving this is via cooperating lineages that
select virus mutants with more bnAb lineage neutralization in
sensitivity than the T/F virus, thus potentiating bnAb affinity
maturation. It has recently been demonstrated that CH103 anti-
body lineage mutations also resulted in bnAb conformational
shifts that led to accommodations of mutational insertions in
Env V5 (Fera et al., 2014).
The contrast in selection of autologous escape mutants by the
CH103 bnAb lineage (Figure 1) and the CH235 nAb lineage (Fig-
ure 4) is striking and suggested a difference in their biology.
Whereas the CH235 nAb lineage led to total escape from identi-
fied lineage members after 30 weeks of infection (Figure 4), the
CH103 bnAb lineage differed in that it was comprised of two
components, the early autologous-only nAbs (UCA through
IA4) and the more mature antibodies (IA3 through CH103,
CH104, CH105, and CH106 bnAbs) with neutralization breadth
(Figure 1). The early CH103 autologous-only nAbs also selected
total escape by week 53, but the later CH103 antibodies with
neutralization breadth did not. Rather, the more mature CH103Cell 158, 481–491, July 31, 2014 ª2014 Elsevier Inc. 487
Figure 7. Schema of Cooperation of B Cell
Lineages in Induction of HIV-1 Broadly
Neutralizing Antibodies
The T/F Env (red Env trimer) likely initiated both the
CH235 and CH103 lineages by binding to their
UCA. The CH235 lineage (dark blue), selected viral
escape mutations in loop D of the CH505 T/F virus
(blue Env timer). The CH103 lineage gradually
accumulated mutations that led to acquisition
of bnAb activity as CH103 lineage affinity matu-
ration progressed. The loop D mutant Envs more
avidly bound CH103 IAs and mature antibodies
than the T/F Env and thus cooperated with the
T/F Env to drive CH103 bnAb B cell lineage
development.bnAbs retained the ability to neutralize select autologous vari-
ants through week 100 (Figure 1). These data suggested that a
component of bnAb development is the retention of ability to
neutralize autologous variants (Figure 1). Thus, the cooperation
between the CH235 nAb lineage and the CH103 bnAb lineage
demonstrated the first step in bnAb lineage development in
which CH103 lineage bnAbs retained the ability to neutralize
autologous virus variants as they matured to neutralize heterolo-
gous viruses. It is critical to determine if the types of cooperating
lineages as seen in CH235-CH103 interactions are the key initi-
ators of bnAb breadth, or if other additional Env-reactive B cell
lineages are required. Against this latter notion was the observa-
tion that multiple loop D Env mutants can likely drive all stages of
the CH103 lineage (Figure 3).
It will be important to determine whether the interaction be-
tween CH235 and CH103 lineages only occurs during a short
window early in viral evolution, or over a longer period of
time. We note in this context that the heavy chain of CH235
derived from VH1-46, which has also been observed to
produce broadly neutralizing CD4bs antibodies like 1B2530
and 8ANC131 (Scheid et al., 2011).
It is also important to note that the CH103 bnAb is a loop bind-
ing CD4bs bnAb in contrast to the VRC01 class of CD4bs bnAb
that recognizes the CD4-binding site in a manner similar to
CD4 (Zhou et al., 2013). Whereas VRC01 class mAbs derive
from restricted VH1-2 paired with a VLJL with a five amino acid
LCDR3, loop binding CD4bs bnAbs have been isolated, which
utilize multiple VHDJH/VLJL pairs (Bonsignori et al., 2014; Corti
et al., 2010; Liao et al., 2013a). It will be key to determine, with488 Cell 158, 481–491, July 31, 2014 ª2014 Elsevier Inc.immunization of CH505 Envs, if either
CH103-like VH4-59, Vl3-1CD4bs lineage
Abs are induced or if other VH usage can
be induced with CD4bs bnAb signatures.
These findings have considerable
importance for HIV-1 vaccine design for
induction of CD4bs bnAbs. First, map-
ping of individual bnAb lineages over
time in those individuals who make them
may not be sufficient for obtaining the
information needed for the design of
protective immunogens for bnAb devel-
opment. Rather, mapping of multipleneutralizing antibody lineages may be required for optimal
choice of immunogen candidates. Second, these data suggest
that induction of one or more neutralizing antibody lineages to
select Env variants with enhanced affinity for bnAb lineage anti-
body members may be required to induce CH103-like CD4bs
HIV-1 neutralizing antibodies. For example, for CH103-like line-
age induction, priming with the transmitted/founder Env and
additional Envs variants such as M6V281A with enhanced binding
to CH235 lineage antibodies, followed by boosting with Env
mutants with enhanced binding to CH103 lineage members, is
likely to be important for experimental vaccine design.
EXPERIMENTAL PROCEDURES
Generation of Pseudoviruses
Env pseudoviruses were produced as described (Kirchherr et al., 2007).
Neutralization Assay
Neutralization activity wasmeasured as a reduction in luciferase activity after a
single round infection of TZM-bl cells as previously described (Li et al., 2005;
Montefiori, 2004).
IFN-g ELISpot Assay
The IFN-g ELISpot assay was performed according to previous descriptions
(Cox et al., 2006). The responses were considered positive if > 50 SFC per
106 PBMCs were detected.
Site-Directed Mutagenesis
Mutants of CH0505.T/F envelope gene were constructed using the Quick
Change II Site-Directed Mutagenesis kit (Agilent Technologies, Santa Clara,
CA). All final env mutants were confirmed by sequencing.
Viral Fitness Assay
The fitness of the Env loop D mutants was determined by comparing to their
cognate CH505 T/F virus in a competitive fitness assay as previous described
(Cai et al., 2007; Song et al., 2012).
Envelope Glycoprotein Expression
The codon-optimized CH505 transmitted/founder and loop D mutant env
genes were generated by de novo synthesis (GeneScript, Piscataway, NJ) or
site-directed mutagenesis in mammalian expression plasmid pcDNA3.1/
hygromycin (Invitrogen, Grand Island, NY) as described (Liao et al., 2013b),
and stored at 80C until use.
B Cell Culture
IgG+ memory cells were isolated from PBMCs using a previously described
protocol (Bonsignori et al., 2011). Cell culture supernatants were screened
for binding to autologous CH505 T/F gp140 and neutralization of the autolo-
gous CH505 w4.3 Env pseudovirus. Culture supernatants that neutralized
CH505 w4.3 were then screened for differential neutralization of the CH505
T/F and M10 mutant viruses.
Isolation of Immunoglobulin V(D)J and VL Gene Segments and
Expression of Recombinant Antibodies
RNA from positive cultures was extracted by using standard procedures
(RNeasy minikit; QIAGEN, Valencia, CA), and the genes encoding Ig VHDJH
and VLJL rearrangements were amplified by RT and nested PCR without clon-
ing by use of a previously reported method (Liao et al., 2009). Sequence base
calling was performed by using Phred. V, D, and J region genes and mutations
were analyzed by using the SoDA information system (Volpe et al., 2006). The
genetic information of the Ig VHDJH and VLJL were annotated using the
method as described (Liao et al., 2013a). For further characterization, the iso-
lated VHDJH/VLJL genes of the observed antibodies from CH505 and in-
ferred VHDJH/VLJL for UCAs and intermediate antibodies were synthesized
(GenScript, Piscataway, NJ) and cloned into pcDNA3.1 plasmid (Invitrogen,
Grand Island, NY) for production of purified recombinant IgG1 antibodies in
293F cells by transient transfection as described previously (Liao et al., 2011).
Inference of UCA and IAs of CH235 Lineage
The five members of the CH235 antibody lineage were used to infer the UCA
and IAs of both heavy and light chains simultaneously using methods
described in (Kepler, 2013).
Direct-Binding ELISA
Direct-binding ELISAs were performed in 384-well plates as previously
described (Bonsignori et al., 2011).
Surface Plasmon Resonance Affinity and Kinetics Measurements
Binding Kd and rate constant (association rate ka, dissociation rate kd) mea-
surements of mAbs to the autologous CH505 gp140 were carried out on
BIAcore 3000 or BIAcore T200 instruments as described (Alam et al., 2007;
Alam et al., 2009; Liao et al., 2013a).
Structural Alignment and Loop Modeling
To visualize effects of evolutionary mutations in CH505 variants, such as
sequence insertions and addition of potential glycosylation sites, in the trimeric
viral spike context, the antibody CH103-gp120 complex structure (PGB ID:
4JAN) was aligned to the structure of BG505 SOSIP.664 HIV-1 Env trimer in
complex with VRC-PG04 (PGB ID: 3J5M) by superposing the outer domains
of gp120 in each structure using program package CCP4 (Winn et al., 2011).
Based on the superposed CH103 gp120 structure, possible conformations
of loop insertions in the HIV-1 V1, V2, and V5 loop were modeled with program
Loopy (Xiang et al., 2002). Relative positions and potential clashes between
the HIV-1 V1, V2, and V5 loop and the gp120-bound CH103 were depicted
with program PyMOL (http://www.pymol.org).
Calculation of Changes in Binding Affinity upon Mutation
To evaluate the effects of evolutionary mutations in loop D of CH505 gp120
and affinity maturation mutations in antibody CH103 on binding affinity, wecomputationally estimated the changes in binding affinity caused bymutations
on either loop D of gp120 or CHR L2 of antibody CH103 with the program
BeAtMuSiC (Dehouck et al., 2013; Moretti et al., 2013). This program uses
the known structure of a protein-protein complex to evaluates the change in
binding affinity between two proteins caused by single-site mutations in their
sequence; we observed a high concordance in prediction by this program
and binding data for HIV-1 gp120-antibody complex structures for which
binding data for single-site mutations had been previously determined exper-
imentally (Zhou et al., 2010). Single mutations were modeled using the struc-
ture of mature antibody CH103 in complex with gp120 (PDB ID: 4JAN) while
keeping the protein backbone rigid. Calculations were carried out by reverting
respective amino acid at each position (275, 279, and 281 in the HIV-1 loop D
and 50-52 in CH103 CDR L2) to its counterpart in the T/F virus or germline
antibody.
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